InvestorsHub Logo
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Thursday, 06/11/2020 10:38:52 AM

Thursday, June 11, 2020 10:38:52 AM

Post# of 1162
FDA approves Opdivo monotherapy for second-line esophageal cancer—irrespective of PD-L1 expression:

https://www.businesswire.com/news/home/20200610005910/en

This approval is based on the ATTRACTION-3 study, which had OS HR=0.77 for Opdivo compared to standard second-line chemo.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News